Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.
Feuerstein graduated from Emory University with a bachelor's degree in political science.
Recent Articles By The Author
Vertex Pharma Moves Next-Generation Cystic Fibrosis Drugs Into New Clinical Trials
Vertex hopes the new drugs will improve on the efficacy and tolerability of Orkambi, the first combination therapy approved for cystic fibrosis in 2015.
Bear Thesis on Corbus Pharma Could Cause a Crash Landing for High-Flying Biotech Stock
The market is acting like resunab is a real drug, which is why my investor source is short Corbus.
Global Blood, FDA Reach Agreement on Pivotal Trial Design for Sickle Cell Disease Drug
Global Blood wants to start screening sickle cell disease patients for the phase III study in December with the hope of having top-line results in the first half of 2019.
Alkermes Depression Drug Finds Success on Third Study Attempt
Third time was the charm for Alkermes' experimental antidepressant ALKS 5461.
Gilead Sciences Advances Fatty Liver Drug, Causing Some Head-Scratching
Gilead is under enormous pressure from investors to acquire companies or develop new drugs from its pipeline.